Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LY96 | Q9Y6Y9 | 3/20 | 0.53 |
| ▸ | TLR4 | O00206 | 2/20 | 0.53 |
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.44 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.44 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063341 | 1.00 | LY96 (0.53) | LY96TLR4NAAASMPD1ENPP2 | |
| SCHEMBL3075469 | 0.98 | LY96 (0.55) | LY96TLR4NAAASMPD1ENPP2 | |
| SCHEMBL3082731 | 0.98 | LY96 (0.55) | LY96TLR4NAAASMPD1ENPP2 | |
| SCHEMBL3075504 | 0.95 | LY96 (0.48) | LY96TLR4NAAASMPD1ENPP2 | |
| SCHEMBL3076907 | 0.95 | LY96 (0.48) | LY96TLR4NAAASMPD1ENPP2 | |
| SCHEMBL9004344 | 0.92 | SMPD1 (0.53) | LY96TLR4NAAASMPD1 | |
| SCHEMBL9000966 | 0.91 | SMPD1 (0.55) | LY96TLR4NAAASMPD1ENPP2 | |
| SCHEMBL4285698 | 0.91 | ITPR3 (0.52) | LY96TLR4NAAASMPD1 | |
| SCHEMBL8845346 | 0.87 | ITPR3 (0.43) | LY96TLR4SMPD1 | |
| SCHEMBL5667749 | 0.87 | ITPR3 (0.43) | LY96TLR4SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| EP-2187892-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | Bioneris AB (SE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009038533-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | BIONERIS AB (SE) | 2009-03-26 | — | — | WO | claimed |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | disclosed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | disclosed |
| EP-2187892-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | Bioneris AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009038533-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | BIONERIS AB (SE) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | LY96 3278/4885TLR4 2430/4885NAAA 2602/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | LY96 865/4885TLR4 741/4885NAAA 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.